Figure 3From: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes Impact of EREG mRNA levels on cetuximab-treated patient survival by KRAS tumour mutation. (Blue line: EREG-high, Red line: EREG-low).a) KRAS wild type (p=0.011), b) KRAS mutated (p=0.022).Back to article page